News from pharmamar A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 01, 2019, 17:03 ET Positive results of lurbinectedin Phase II trial (PharmaMar) for the treatment of relapsed small cell lung cancer are presented at ASCO

The results of PharmaMar's (MSE: PHM) Phase II study with lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer were...


Oct 19, 2018, 08:30 ET Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial

Sylentis, PharmaMar Group (MCE: PHM), has announced today that it has reached its target of recruiting 300 patients for the Phase III trial "HELIX"...


Sep 24, 2018, 16:46 ET PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer

The results are from Cohort B of the Phase I/II Study in patients with relapsed Small Cell Lung Cancer (SCLC). This study preceded the Phase III...


Sep 07, 2018, 08:30 ET PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares

Pharma Mar, S.A. (MCE: PHM) ("Pharma Mar" or the "Company") is announcing its intention to conduct a registered public offering of American...


Sep 06, 2018, 08:30 ET PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference

The results are from Cohort B of the Phase I/II Study in patients with small-cell lung cancer, a study that predated the Phase III ATLANTIS Study at...


Aug 03, 2018, 08:00 ET The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the treatment of small cell lung cancer (SCLC)...


Jul 31, 2018, 05:25 ET PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment

ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries Top line data ...


Jul 27, 2018, 08:18 ET PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe

PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan...


Jun 26, 2018, 01:13 ET PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan

PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from Chugai PharmaMar progresses in ...


Jun 12, 2018, 05:19 ET PharmaMar sigla un accordo di licenza per la commercializzazione e la distribuzione di Aplidin® con Pint Pharma International

PharmaMar (MCE: PHM) ha annunciato oggi di aver firmato con Pint Pharma International, S.A. un contratto di licenza per la commercializzazione e la...


Jun 12, 2018, 05:17 ET PharmaMar und Pint Pharma International unterzeichnen einen Kommerzialisierungs- und Vertriebslizenzvertrag für Aplidin®

PharmaMar (MCE: PHM) hat heute die Unterzeichnung eines Kommerzialisierungs- und Vertriebslizenzvertrags mit Pint Pharma International, S.A. für das...


Jun 12, 2018, 05:15 ET PharmaMar signe un accord de licence pour la commercialisation et la distribution d'Aplidin® avec Pint Pharma International

PharmaMar (MCE: PHM) a annoncé aujourd'hui la signature d'un accord de licence avec Pint Pharma International, S.A. pour la commercialisation et la...


Jun 11, 2018, 08:30 ET PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International

PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A....


Jun 05, 2018, 08:30 ET PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

Abstract #8018 The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. Of...


Jun 05, 2018, 08:30 ET PharmaMar presenta nella sessione orale ad ASCO: sopravvivenza complessiva regolata con Plitidepsin nello studio ADMYRE

Abstract #8018 Presentati i modelli di dati sulla sopravvivenza globale nella valutazione statistica dell'impatto del crossover nello studio ADMYRE....


Jun 05, 2018, 08:30 ET PharmaMar-Präsentation bei mündlicher Vortragssitzung auf ASCO: Bereinigtes Gesamtüberleben mit Plitidepsin aus ADMYRE-Studie

Abstract #8018 Präsentiert wurden die modellierten Daten zum Gesamtüberleben aus der statistischen Auswertung des Crossover-Effekts aus der...


Jun 05, 2018, 08:30 ET PharmaMar fait une présentation orale au Congrès de l'ASCO : survie globale ajustée de l'étude ADMYRE avec la plitidepsine

Résumé numéro 8018 Les données modélisées sur la survie globale par l'évaluation statistique de l'impact de l'étude croisée (cross-over) ADMYRE ont...


Jun 04, 2018, 11:06 ET PharmaMar presenta nuovi risultati con la Lurbinectedina come agente singolo in pazienti con carcinoma polmonare recidivante a piccole cellule ad ASCO 2018

Abstract #8570 Lo studio a canestro di fase II, che ha cominciato a reclutare 15 pazienti con cancro al polmone recidivante a piccole cellule, è...


Jun 04, 2018, 08:30 ET PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

Abstract #8570 The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to target enrolment ...


Jun 04, 2018, 03:45 ET PharmaMar präsentiert auf ASCO 2018 neue Ergebnisse zu Lurbinectedin als Monotherapie bei Patienten mit rezidiviertem kleinzelligem Lungenkarzinom

Abstract #8570 Die Phase-II-Basket-Studie, für die ursprünglich 15 Patienten mit rezidiviertem kleinzelligem Lungenkarzinom rekrutiert wurden, wurde...


Jun 04, 2018, 01:27 ET ASCO 2018: PharmaMar présente de nouveaux résultats avec la lurbinectédine administrée en agent unique chez des patients souffrant d'un cancer du poumon à petites cellules récidivant

Résumé #8570 L'essai panier de phase II, qui a commencé avec le recrutement de 15 patients souffrant d'un cancer du poumon à petites cellules, a été...


May 29, 2018, 08:30 ET Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)

PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that...


May 17, 2018, 08:30 ET PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018

During the Congress of the American Society of Clinical Oncology (ASCO) that will be held form the 1st to the 5th of June in Chicago (USA), PharmaMar ...


May 07, 2018, 08:30 ET Sylentis Announces New Data on the Treatment of Allergic Conjunctivitis

• The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%[i] . • The ARVO meeting...


May 04, 2018, 08:30 ET Sylentis Presented New Results for the Treatment of Age Associated Macular Degeneration

Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has been held from the 29th of...